Treatment Information

Back

Colon Cancer treatment details. Chemotherapy.

Antwerp University Hospital, Edegem, Belgium.

Survival: monthsCountry:Belgium
Toxiciy Grade:5City/State/Province:Edegem
Treatments:ChemotherapyHospital:Antwerp University Hospital
Drugs:Journal:Link
Date:Feb 2013

Description:

Patients:
This phase 2 study involved previously treated metastatic colorectal cancer patients who were separated into two treatment groups. Group A consisted of 95 patients with a median age of 56 years and 63% male. Group B had 49 patients with a median age of 55 years and 49% male.

Treatment:
Patients in group A were treated with the chemotherapy combination called FOLFIRI (irinotecan, leucovorin, 5-fluorouracil) and the biologic therapy agent trebananib, which is an inhibitor of the angiopoietin proteins and interferes with tumor growth.

Patients in group B were treated with the chemotherapy combination called FOLFIRI (irinotecan, leucovorin, 5-fluorouracil) only.

Toxicities:
In group A, there were six reported deaths due to adverse events including swelling of the lungs, diarrhea, and heart attack. Grade 3-4 neutropenia and fatigue were also reported.

There were three deaths in group B due to adverse events including cardiorespiratory arrest. Grade 3-4 neutropenia, vomiting, and abdominal pain were also reported.

Results:
The median overall survival for groups A and B was 11.9 and 8.8 months, respectively.

Support:
This study was partially supported by Amgen, Inc.

Correspondence: Dr. M Peeters; email: [email protected]



Back